Carl Goldfischer
Equibles does not estimate personal net worth.
About Carl Goldfischer
Earlier roles on record: Board Member at Enliven Therapeutics, Inc. (ELVN) until February 23, 2023. Damora Therapeutics, Inc. reported in an 8-K filed March 23, 2026 that Carl Goldfischer resigned as director, effective March 23, 2026. Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that Carl Goldfischer resigned as Board, effective February 23, 2023.
“Effective as of March 23, 2026, Amit Munshi, Carl Goldfischer and Jayson Dallas resigned from the Board.”
“Pursuant to the Merger Agreement, on February 23, 2023, immediately prior to and effective upon the closing of the Merger, David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Affiliation history
-
Start not stated–2023-02-23